 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
 |
Online Early |
|
Current Issue
Core Evidence
Vol. 2, No. 4
July, 2008
ISSN: 1555-1741 |
|
Free Trial |
|
|
Sample |
|
|
|
|
|
|
|
|
|
|
|
|
| Call For Papers |
Core Evidence |
Opportunity to publish in an international,
peer-reviewed, indexed journal.
If you are involved in making prescribing
decisions or drug choices in the clinical, formulary, or policy
setting, have you considered getting your work published?
Core Evidence is the first peer-reviewed journal
to evaluate the outcomes evidence central to rational drug
selection and effective clinical decisions. Launched in July
2005, the journal meets the need for published, independent,
evidence-based reviews of new drugs. We are now expanding
the scope of the journal and inviting submissions of original
research and reviews.
|
Key facts about
Core Evidence: |
 |
Audience: Core
Evidence reaches an international audience of medicines
information professionals, formulary decision makers,
prescribing advisers and pharmacists, practicing physicians,
healthcare administrators and commissioners |
|
Indexing: Core Evidence
is abstracted and indexed in EMBASE, Scopus, CINAHL, and
HEED, and syndicated on Medscape.com. Indexing in other
major databases (e.g. Medline) is being applied for |
|
Peer review: Core Evidence
is peer reviewed by an internationally recognised honorary
editorial board and review panel |
|
Print and online: Core
Evidence is available in print, and online at www.ingenta.com |
|
Open access: to ensure rapid
free availability online, Core Evidence offers
an open access option to authors |
|
| Share your work and communicate
with your peers and colleagues around the world. Contact
editor@coreevidence.com
or call +44 1565 752114 for more details. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
